Puma Biotechnology, Inc. (PBYI)

Puma Biotechnology Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	235.64	228.03	253.16	225.11	272.26
Revenue Growth (YoY)	3.34%	-9.92%	12.46%	-17.32%	8.47%
Cost of Revenue	62.68	55.09	63.7	39.37	36.82
Gross Profit	172.96	172.94	189.45	185.74	235.45
Selling, General & Admin	89.93	89.98	116.29	118.49	141.64
Research & Development	50.38	52.24	71.87	97.65	132.85
Other Operating Expenses	0	7	0	0	0
Operating Expenses	140.32	149.22	188.16	216.14	274.49
Operating Income	32.64	23.72	1.29	-30.4	-39.05
Interest Expense / Income	13.33	11.59	12.81	14.05	15.02
Other Expense / Income	-3.36	11.67	17.29	15.34	21.48
Pretax Income	22.67	0.46	-28.8	-59.79	-75.54
Income Tax	1.08	0.46	0.32	0.21	0.05
Net Income	21.59	0	-29.13	-60	-75.6
Net Income Growth	1079450.00%	-	-	-	-
Shares Outstanding (Basic)	47	45	41	40	39
Shares Outstanding (Diluted)	48	45	41	40	39
Shares Change	5.83%	10.56%	2.69%	2.08%	2.18%
EPS (Basic)	0.46	-	-0.72	-1.52	-1.95
EPS (Diluted)	0.45	-	-0.72	-1.52	-1.95
Free Cash Flow	26.87	-15.83	20.65	0.73	22.07
Free Cash Flow Per Share	0.57	-0.35	0.51	0.02	0.57
Gross Margin	73.40%	75.84%	74.84%	82.51%	86.48%
Operating Margin	13.85%	10.40%	0.51%	-13.51%	-14.34%
Profit Margin	9.16%	0.00%	-11.51%	-26.65%	-27.77%
Free Cash Flow Margin	11.40%	-6.94%	8.16%	0.32%	8.11%
Effective Tax Rate	4.78%	99.56%	-	-	-
EBITDA	47.52	21.89	-4.69	-35.71	-52.45
EBITDA Margin	20.17%	9.60%	-1.85%	-15.86%	-19.26%
Depreciation & Amortization	11.52	9.84	11.31	10.03	8.08
EBIT	36	12.05	-16	-45.74	-60.52
EBIT Margin	15.28%	5.28%	-6.32%	-20.32%	-22.23%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).